Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$284.0KBeat by $227.6K
EPS-$1.05Miss by $0.02
Revenue estimate$56.4K
EPS estimate-$1.03
“We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company. Our team's focus on execution continues in the commercial setting and we are happy with the early launch feedback from physicians and patients, positive payer engagement, and our progress in building enthusiasm for Lumvoa as a new treatment option. In parallel, we continue to advance our R&D pipeline toward a planned BLA submission for elegrobart in the first quarter of 2027, and are on track to deliver on clinical development milestones for our FcRn and TSHR programs in the second half of this year. With a strong balance sheet, we are well positioned to continue executing across our commercial and development priorities.”
Steve Mahoney

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$4.0M
EPS estimate-$0.99

Financials

Q2 2026

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$2.54B+67.2%
Enterprise value$2.49B+74.7%
P/S35.7×-4,949×

Profitability

See full
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

FAQ

When did Viridian Therapeutics, Inc. report Q2 2026 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Viridian Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $284.0K and eps of $-1.05 for Q2 2026.
Did Viridian Therapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $56.4K by $227.6K. EPS missed the consensus estimate of $-1.03 by $0.02.
How did Viridian Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 278.7% from $75.0K a year earlier and eps declined 5.0% from $-1.00.
Where can I find Viridian Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336691) and the 10-Q periodic report (0001590750-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.